Abstract: Disclosed are a crystal form II of a thienopyridine derivative bisulfate and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form II represented by the 2? diffraction angle exhibits characteristic diffraction peaks at 12.86°, 13.58°, 15.58°, 17.64°, 18.42°, 21.56°, 22.90°, 23.70° and 24.64°. The crystal form can be used as an active ingredient for preparing a pharmaceutical composition for preventing and treating diseases caused by thrombi. Compared with the original crystal form, the crystal form II of the invention has a better stability, with denser bulk solid particles, and is less susceptible to static electricity, and has better fluidity and compressibility, and when used as an active ingredient for preparing a pharmaceutical composition, the pharmaceutical preparation prepared with the crystal form II has a stronger stability.

Abstract: Disclosed are a crystal form II of a thienopyridine derivative bisulfate and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form II represented by the 2? diffraction angle exhibits characteristic diffraction peaks at 12.86°, 13.58°, 15.58°, 17.64°, 18.42°, 21.56°, 22.90°, 23.70° and 24.64°. The crystal form can be used as an active ingredient for preparing a pharmaceutical composition for preventing and treating diseases caused by thrombi. Compared with the original crystal form, the crystal form II of the invention has a better stability, with denser bulk solid particles, and is less susceptible to static electricity, and has better fluidity and compressibility, and when used as an active ingredient for preparing a pharmaceutical composition, the pharmaceutical preparation prepared with the crystal form II has a stronger stability.